Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 724-733

  McKinnon, Peggy S ^a   Neuhauser, Melinda M ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN; CLAVULANIC ACID; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GYNECOLOGIC INFECTION; HUMAN; MAJOR CLINICAL STUDY; RESPIRATORY TRACT INFECTION; SKIN INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; AMPICILLIN; ANALYSIS OF VARIANCE; BACTERIAL INFECTIONS; CLAVULANIC ACIDS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULBACTAM; TICARCILLIN; TREATMENT OUTCOME; UNITED STATES;

EID: 0033001787     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.724.31537     Document Type: Article

References (28)

1. Rolinson GN. Evolution of beta-lactamase inhibitors. Surg Gynecol Obstet 1990;172(suppl):11-16.
2. Sutherland R. Development of beta-lactamase inhibitors. J Reprod Med 1990;35(suppl):307-12.
3. Neu HC. β-lactamases, β-lactamase inhibitors, and skin and skin-structure infections. J Am Acad Dermatol 1990;22: 896-904.
4. Jones RN. Role of new cephamycins in the management of obstetric and gynecologic infections. J Reprod Med 1990;35(suppl):1070-7.
5. Jones RN. In vitro evaluations of aminopenicillin/β-lactamase inhibitor combinations. Drugs 1988;35(suppl 7):17-26.
6. Fuchs PC, Barry AL, Thornsberry C, Jones RN. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother 1984;25:392-4.
7. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a β-lactamase inhibitor combination for serious intra-abdominal infections. Ann Surg 1993;217:115-21.
8. Faro S. Ticarcillin/clavulanate. An alternative to combination antibiotic therapy for treating soft tissue pelvic infections in women. J Reprod Med 1990;35(suppl):353-8.
9. Kosseim M, Ronald A, Plummer FA, D'Costa L, Brunham RC. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam. Antimicrob Agents Chemother 1991;35:1651-6.
10. Hemsell DL, Bawdon RE, Hemsell PG, Nobles BJ, Heard MC. Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin. J Int Med Res 1990;18(suppl 4):85D-9.
11. Scalambrino S, Mangioni C, Milani R, et al. Sulbactam/ ampicillin versus cefotetan in the treatment of obstetric and gynecologic infections. Int J Gynecol Obstet 1989;2(suppl):21-8.
12. Kulhanjian J, Dunphy MG, Hamstra S, et al. Randomized comparative study of ampicillin-sulbactam vs. ceftriaxone for treatment of soft tissue and skeletal infections in children. Pediatr Infect Dis J 1989;8:605-10.
13. File TM Jr, Tan JS. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. Rev Infect Dis 1991;13(suppl 9):S733-6.
14. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93.
15. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994;28:384-9.
16. Moran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. Ann Pharmacother 1991;25:546-52.
17. McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and genlamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994;83:998-1004.
18. Stovall TG, Thorpe EM Jr, Ling FW. Treatment of post-cesarean section endometritis with ampicillin and sulbactam or clindamycin and gentamicin. J Reprod Med 1993;38:843-8.
19. Martens MG, Faro S, Maccato M, Hammill HA, Riddle G. Prevalence of β-lactamase enzyme production in bacteria isolated from women with postpartum endometritis. J Reprod Med 1993;38:795-8.
20. Jauregui L, Minns P, Hageage G. A comparison of ampicillin-sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalized patients. J Chemother 1995;7:153-6.
21. Geckler RW. A comparison of ampicillin-sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. Clin Ther 1994;16:662-72.
22. Guneren MF. Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicenter trial. Drugs 1988;35(suppl 7):57-68.
23. Ah Chong K, Yip AW, Lee FC, Chiu KM. Comparison of prophylactic ampicillin-sulbactam with gentamicin and metronidazole in elective colorectal surgery: a randomized clinical study. J Hosp Infect 1994;27:149-54.
24. Rijhsinghani A, Savopoulos SE, Walters JK, Huggins G, Hibbs JR. Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial. Am J Perinatol 1995;12:322-4.
25. Lawrenz CA, Cole P, Theodorou A, Cook RL, Bermann L. Therapeutic interchange of ampicillin-sulbactam for cefoxitin. Am J Hosp Pharm 1991;48:2150-4.
26. Resnik E, Harger JH, Kuller JA. Early postpartum endometritis. Randomized comparison of ampicillin-sulbactam vs. ampicillin, gentamicin and clindamycin. J Reprod Med 1994;39:467-72.
27. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997;24:57-63.
28. Markowitz SM, Wells VD, Williams DS, Stuart CG, Coudron PE, Wong ES. Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis. Antimicrob Agents Chemother 1991;35:1075-80.